RSS | Login | Register

Treanda

March 27, 2008

Cephalon has been conducting traditional pre-launch activities for Treanda, the first new therapy approved for the treatment of chronic lymphocytic leukemia (CLL) since 2001.

Ibudone

March 20, 2008

Ibudone's rollout appears to be in line with most branded generic products.

Arcalyst

March 20, 2008

Arcalyst is approved for an orphan disease whose US incidence rate is one-in-a-million patients.

Tekturna HCT

March 13, 2008

The first fixed-dose combination involving Novartis' first-in-class oral renin inhibitor, Tekturna with hydrochlorothiazide (HCT) was approved in the US in January 2008.

Pristiq

March 13, 2008

Wyeth is expected to mount a large sales campaign for Pristiq, a successor drug to Effexor XR, Wyeth's top-selling SNRI whose patent expires in 2010.

Flector Patch

March 06, 2008

Alpharma's ability to strengthen its position in the pain-management space will depend on the launch of Flector Patch, a topical NSAID approved for pain.

Fosteum

March 06, 2008

Fosteum, a prescription medical food product, is being positioned to fill a niche that small-molecule drugs may not.

Simcor

February 28, 2008

In the race to combine niacin with a generic version of Merck's off-patent statin simvastatin, Abbott appears to have pole position.

Recothrom

February 28, 2008

Recothrom Thrombin is ZymoGenetics' first commercial product, and the firm is pulling out all the stops.

Voltaren Gel

February 07, 2008

With the lapse of patent protection for Voltaren in many key markets, Novartis is taking the usual route to extending product life cycle—new formulations.

« Previous